TY - JOUR
T1 - Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection
AU - Codagnone, M.
AU - Cianci, E.
AU - Lamolinara, A.
AU - Mari, V. C.
AU - Nespoli, A.
AU - Isopi, E.
AU - Mattoscio, D.
AU - Arita, M.
AU - Bragonzi, A.
AU - Iezzi, M.
AU - Romano, M.
AU - Recchiuti, A.
N1 - Funding Information:
This work was supported in part by the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement 294187 FP7-PEOPLE-CIG-2011, the Italian Cystic Fibrosis Foundation (FFC#21/2014), the Regione Abruzzo under the Piano Speciale Multiasse Reti per l’Alta Formazione–POFSE 2007–2013, and the Italian Ministry of Health (GR-2011-02349730) (to A.R.). The FFC#21/2014 project was entirely adopted by Unicredit, Iniziativa di Natale FFC 2014, Gruppo di sostegno FFC di Isili (CA), Delegazioni FFC di Soverato (CT), San Costantino Calabro (VV), and Montescaglioso Matera (MT). We thank Alice Rossi, Ida De Fino, and Serena Ranucci for skillful assistance with chronic infection experiments and Sara Di Silvestre for help with HPAEC isolation. The authors thank B. Tümmler (Medizinische Hochschule Hannover, Germany) for supplying P. aeruginosa clinical strain RP73.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Pseudomonas aeruginosa lung infection is a main cause of disability and mortality worldwide. Acute inflammation and its timely resolution are crucial for ensuring bacterial clearance and limiting tissue damage. Here, we investigated protective actions of resolvin (Rv) D1 in lung infection induced by the RP73 clinical strain of P. aeruginosa. RvD1 significantly diminished bacterial growth and neutrophil infiltration during acute pneumonia caused by RP73. Inoculum of RP73, immobilized in agar beads, resulted in persistent lung infection up to 21 days, leading to a non resolving inflammation reminiscent of human pathology. RvD1 significantly reduced bacterial titer, leukocyte infiltration, and lung tissue damage. In murine lung macrophages sorted during P. aeruginosa chronic infection, RvD1 regulated the expression of Toll-like receptors, downstream genes, and microRNA (miR)-21 and 155, resulting in reduced inflammatory signaling. In vitro, RvD1 enhanced phagocytosis of P. aeruginosa by neutrophils and macrophages, recapitulating its in vivo actions. These results unveil protective functions and mechanisms of action of RvD1 in acute and chronic P. aeruginosa pneumonia, providing evidence for its potent pro-resolution and tissue protective properties on airway mucosal tissue during infection.
AB - Pseudomonas aeruginosa lung infection is a main cause of disability and mortality worldwide. Acute inflammation and its timely resolution are crucial for ensuring bacterial clearance and limiting tissue damage. Here, we investigated protective actions of resolvin (Rv) D1 in lung infection induced by the RP73 clinical strain of P. aeruginosa. RvD1 significantly diminished bacterial growth and neutrophil infiltration during acute pneumonia caused by RP73. Inoculum of RP73, immobilized in agar beads, resulted in persistent lung infection up to 21 days, leading to a non resolving inflammation reminiscent of human pathology. RvD1 significantly reduced bacterial titer, leukocyte infiltration, and lung tissue damage. In murine lung macrophages sorted during P. aeruginosa chronic infection, RvD1 regulated the expression of Toll-like receptors, downstream genes, and microRNA (miR)-21 and 155, resulting in reduced inflammatory signaling. In vitro, RvD1 enhanced phagocytosis of P. aeruginosa by neutrophils and macrophages, recapitulating its in vivo actions. These results unveil protective functions and mechanisms of action of RvD1 in acute and chronic P. aeruginosa pneumonia, providing evidence for its potent pro-resolution and tissue protective properties on airway mucosal tissue during infection.
UR - http://www.scopus.com/inward/record.url?scp=85038834357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038834357&partnerID=8YFLogxK
U2 - 10.1038/mi.2017.36
DO - 10.1038/mi.2017.36
M3 - Article
C2 - 28422188
AN - SCOPUS:85038834357
SN - 1933-0219
VL - 11
SP - 35
EP - 49
JO - Mucosal Immunology
JF - Mucosal Immunology
IS - 1
ER -